OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
MENLO PARK, Calif., Aug. 09, 2017 -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2017.
For the second quarter of 2017, the company reported a net loss of $6.4 million, or $0.04 per share, compared to $8.6 million, or $0.05 per share, for the comparable 2016 period. Net loss for the first six months of 2017 was $13.6 million, or $0.09 per share, compared to $17.5 million, or $0.11 per share, for the comparable 2016 period. The company ended the second quarter of 2017 with $117.2 million in cash and investments.
Revenues for the three and six months ended June 30, 2017 were $174,000 and $711,000, respectively, compared to $211,000 and $960,000 for the comparable 2016 periods. Revenues for the three and six month periods ending June 30, 2017 and 2016 included royalty and license fee revenues under various non-imetelstat license agreements.
Total operating expenses for the three and six months ended June 30, 2017 were $6.9 million and $14.9 million, respectively, compared to $9.1 million and $18.9 million for the comparable 2016 periods. Research and development expenses for the three and six months ended June 30, 2017 were $2.5 million and $5.9 million, respectively, compared to $4.6 million and $9.6 million for the comparable 2016 periods. The decrease in research and development expenses for the three and six month periods ending June 30, 2017, compared to the same periods in 2016, primarily reflects lower costs for the proportionate share of clinical development expenses under the collaboration with Janssen Biotech, Inc. and reduced personnel related expenses. General and administrative expenses for the three and six months ended June 30, 2017 were $4.4 million and $9.1 million, respectively, compared to $4.5 million and $9.3 million for the comparable 2016 periods. The decrease in general and administrative expenses for the three and six month periods ending June 30, 2017, compared to the same periods in 2016, primarily reflects lower consulting costs.
Interest and other income for the three and six months ended June 30, 2017 was $346,000 and $678,000, respectively, compared to $293,000 and $549,000 for the comparable 2016 periods. The increase in interest and other income for the three and six month periods ending June 30, 2017, compared to the same periods in 2016, primarily reflects higher yields on the company’s marketable securities portfolio.
Due to the recent announcement and conference call on updates to the clinical development plans for imetelstat, Geron’s management will not be hosting a separate conference call in connection with these financial results.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
Financial table follows.
| GERON CORPORATION | ||||||||||||||||
| CONDENSED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (UNAUDITED) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| (In thousands, except share and per share data) | 2017 | 2016 | 2017 | 2016 | ||||||||||||
| Revenues: | ||||||||||||||||
| License fees and royalties | $ | 174 | $ | 211 | $ | 711 | $ | 960 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 2,499 | 4,575 | 5,873 | 9,608 | ||||||||||||
| General and administrative | 4,406 | 4,547 | 9,063 | 9,340 | ||||||||||||
| Total operating expenses | 6,905 | 9,122 | 14,936 | 18,948 | ||||||||||||
| Loss from operations | (6,731 | ) | (8,911 | ) | (14,225 | ) | (17,988 | ) | ||||||||
| Interest and other income | 346 | 293 | 678 | 549 | ||||||||||||
| Interest and other expense | (20 | ) | (19 | ) | (41 | ) | (40 | ) | ||||||||
| Net loss | $ | (6,405 | ) | $ | (8,637 | ) | $ | (13,588 | ) | $ | (17,479 | ) | ||||
| Basic and diluted net loss per share: | ||||||||||||||||
| Net loss per share | $ | (0.04 | ) | $ | (0.05 | ) | $ | (0.09 | ) | $ | (0.11 | ) | ||||
| Shares used in computing net loss per share | 159,182,367 | 158,998,931 | 159,171,959 | 158,947,485 | ||||||||||||
| CONDENSED BALANCE SHEETS | |||||
| June 30, | December 31, | ||||
| (In thousands) | 2017 | 2016 | |||
| (Unaudited) | (Note 1) | ||||
| Current assets: | |||||
| Cash, cash equivalents and restricted cash | $ | 6,874 | $ | 13,078 | |
| Current marketable securities | 88,239 | 102,035 | |||
| Other current assets | 6,953 | 999 | |||
| Total current assets | 102,066 | 116,112 | |||
| Noncurrent marketable securities | 22,076 | 13,954 | |||
| Property and equipment, net | 140 | 183 | |||
| $ | 124,282 | $ | 130,249 | ||
| Current liabilities | $ | 11,274 | $ | 7,869 | |
| Stockholders’ equity | 113,008 | 122,380 | |||
| $ | 124,282 | $ | 130,249 | ||
Note 1: Derived from audited financial statements included in the company’s annual report on Form 10-K for the year ended December 31, 2016.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
